|
1
|
Hunger SP and Mullighan CG: Acute
lymphoblastic leukemia in children. N Engl J Med. 373:1541–1552.
2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rose-Inman H and Kuehl D: Acute leukemia.
Hematol Oncol Clin North Am. 31:1011–1028. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Tallen G, Ratei R, Mann G, Kaspers G,
Niggli F, Karachunsky A, Ebell W, Escherich G, Schrappe M,
Klingebiel T, et al: Long-term outcome in children with relapsed
acute lymphoblastic leukemia after time-point and site-of-relapse
stratification and intensified short-course multidrug chemotherapy:
Results of trial ALL-REZ BFM 90. J Clin Oncol. 28:2339–2347.
2010.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ronson A, Tvito A and Rowe JM: Treatment
of relapsed/refractory acute lymphoblastic leukemia in adults. Curr
Oncol Rep. 18(39)2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Kuhlen M, Willasch AM, Dalle JH, Wachowiak
J, Yaniv I, Ifversen M, Sedlacek P, Guengoer T, Lang P, Bader P, et
al: Outcome of relapse after allogeneic HSCT in children with ALL
enrolled in the ALL-SCT 2003/2007 trial. Br J Haematol. 180:82–89.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Belver L and Ferrando A: The genetics and
mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer.
16:494–507. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Hefazi M and Litzow MR: Recent advances in
the biology and treatment of T cell acute lymphoblastic leukemia.
Curr Hematol Malig Rep. 13:265–274. 2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Teachey DT and Pui CH: Comparative
features and outcomes between paediatric T-cell and B-cell acute
lymphoblastic leukaemia. Lancet Oncol. 20:e142–e154.
2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Ghelli Luserna Di Rorà A, Iacobucci I,
Imbrogno E, Papayannidis C, Derenzini E, Ferrari A, Guadagnuolo V,
Robustelli V, Parisi S, Sartor C, et al: Prexasertib, a Chk1/Chk2
inhibitor, increases the effectiveness of conventional therapy in
B-/T-cell progenitor acute lymphoblastic leukemia. Oncotarget.
7:53377–53391. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bartel DP: MicroRNA: Genomics, biogenesis,
mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Shukla GC, Singh J and Barik S: MicroRNAs:
Processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
|
12
|
Zhao JJ, Chu ZB, Hu Y, Lin J, Wang Z,
Jiang M, Chen M, Wang X, Kang Y, Zhou Y, et al: Targeting the
miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance
in multiple myeloma. Cancer Res. 75:4384–4397. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Liu H, Chang JK, Hou JQ, Zhao ZH and Zhang
LD: Inhibition of miR-221 influences bladder cancer cell
proliferation and apoptosis. Eur Rev Med Pharmacol Sci.
21:3193–3199. 2017.PubMed/NCBI
|
|
14
|
Zhou L, Jiang F, Chen X, Liu Z, Ouyang Y,
Zhao W and Yu D: Downregulation of miR-221/222 by a microRNA sponge
promotes apoptosis in oral squamous cell carcinoma cells through
upregulation of PTEN. Oncol Lett. 12:4419–4426. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chistiakov DA, Sobenin IA, Orekhov AN and
Bobryshev YV: Human miR-221/222 in physiological and
atherosclerotic vascular remodeling. Biomed Res Int.
2015(354517)2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Marques-Rocha JL, Samblas M, Milagro FI,
Bressan J, Martínez JA and Marti A: Noncoding RNAs, cytokines, and
inflammation-related diseases. FASEB J. 29:3595–3611.
2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Göekbuget N, Dombret H, Ribera JM,
Fielding AK, Advani A, Bassan R, Chia V, Doubek M, Giebel S,
Hoelzer D, et al: International reference analysis of outcomes in
adults with B-precursor Ph-negative relapsed/refractory acute
lymphoblastic leukemia. Haematologica. 101:1524–1533.
2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Gökbuget N, Stanze D, Beck J, Diedrich H,
Horst HA, Hüttmann A, Kobbe G, Kreuzer KA, Leimer L, Reichle A, et
al: Outcome of relapsed adult lymphoblastic leukemia depends on
response to salvage chemotherapy, prognostic factors, and
performance of stem cell transplantation. Blood. 120:2032–2041.
2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Oriol A, Vives S, Hernández-Rivas JM,
Tormo M, Heras I, Rivas C, Bethencourt C, Moscardó F, Bueno J,
Grande C, et al: Outcome after relapse of acute lymphoblastic
leukemia in adult patients included in four consecutive
risk-adapted trials by the PETHEMA study group. Haematologica.
95:589–596. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Dentelli P, Traversa M, Rosso A, Togliatto
G, Olgasi C, Marchiò C, Provero P, Lembo A, Bon G, Annaratone L, et
al: miR-221/222 control luminal breast cancer tumor progression by
regulating different targets. Cell Cycle. 13:1811–1826.
2014.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
Qin J and Luo M: MicroRNA-221 promotes
colorectal cancer cell invasion and metastasis by targeting RECK.
FEBS Lett. 588:99–104. 2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lu GJ, Dong YQ, Zhang QM, Di WY, Jiao LY,
Gao QZ and Zhang CG: miRNA-221 promotes proliferation, migration
and invasion by targeting TIMP2 in renal cell carcinoma. Int J Clin
Exp Pathol. 8:5224–5229. 2015.PubMed/NCBI
|
|
24
|
Ye X, Bai W, Zhu H, Zhang X, Chen Y, Wang
L, Yang A, Zhao J and Jia L: MiR-221 promotes
trastuzumab-resistance and metastasis in HER2-positive breast
cancers by targeting PTEN. BMB Rep. 47:268–273. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Salmena L, Carracedo A and Pandolfi PP:
Tenets of PTEN tumor suppression. Cell. 133:403–414.
2008.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Fischer B, Frei C, Moura U, Stahel R and
Felley-Bosco E: Inhibition of phosphoinositide-3 kinase pathway
down regulates ABCG2 function and sensitizes malignant pleural
mesothelioma to chemotherapy. Lung Cancer. 78:23–29.
2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Rahmani M, Aust MM, Attkisson E, Williams
DC Jr, Ferreira-Gonzalez A and Grant S: Dual inhibition of Bcl-2
and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in
human myeloid leukemia cells through a GSK3- and Bim-dependent
mechanism. Cancer Res. 73:1340–1351. 2013.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhou BH, Tan PP, Jia LS, Zhao WP, Wang JC
and Wang HW: PI3K/AKT signaling pathway involvement in
fluoride-induced apoptosis in C2C12 cells. Chemosphere.
199:297–302. 2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Martini M, De Santis MC, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Vachhani P, Bose P, Rahmani M and Grant S:
Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL
inhibition in AML. Physiol Genomics. 46:448–456. 2014.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Radha G and Raghavan SC: BCL2: A promising
cancer therapeutic target. Biochim Biophys Acta Rev Cancer.
1868:309–314. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Brown LM, Hanna DT, Khaw SL and Ekert PG:
Dysregulation of BCL-2 family proteins by leukemia fusion genes. J
Biol Chem. 292:14325–14333. 2017.PubMed/NCBI View Article : Google Scholar
|
